Zai Lab Limited (ZLAB)

14.22 +0.50 (+3.64%) At close: 04:00PM EDT

Zai Lab Limited

Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,175

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ying Du Ph.D.	Founder, Chairperson & CEO	1.67M	N/A	1966
Mr. Joshua L. Smiley	President & COO	647.11k	N/A	1970
Dr. Rafael G. Amado M.D.	President and Head of Global Oncology Research & Development	477k	N/A	1964
Dr. Harald Reinhart M.D.	President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases	923.33k	68.6k	1952
Dr. Yajing Chen Ph.D.	Chief Financial Officer	N/A	N/A	N/A
Dr. Peter Huang Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Christine Chiou	Senior VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Frazor Titus Edmondson III, J.D.	Chief Legal Officer & Corporate Secretary	829k	N/A	1966
Ms. Ann E. Beasley J.D.	Chief Compliance Officer	N/A	N/A	N/A
Dr. Ning Xu M.D.	Executive VP & Head of Clinical Operations	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Corporate governance

Zai Lab Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.